1272 related articles for article (PubMed ID: 30674625)
1. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
2. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
Knudsen ML; Ljungberg K; Tatoud R; Weber J; Esteban M; Liljeström P
PLoS One; 2015; 10(2):e0117042. PubMed ID: 25643354
[TBL] [Abstract][Full Text] [Related]
3. DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost.
Öhlund P; García-Arriaza J; Zusinaite E; Szurgot I; Männik A; Kraus A; Ustav M; Merits A; Esteban M; Liljeström P; Ljungberg K
Sci Rep; 2018 Aug; 8(1):12459. PubMed ID: 30127450
[TBL] [Abstract][Full Text] [Related]
4. High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.
Gómez CE; Perdiguero B; Cepeda MV; Mingorance L; García-Arriaza J; Vandermeeren A; Sorzano CÓ; Esteban M
J Virol; 2013 Jul; 87(13):7282-300. PubMed ID: 23596307
[TBL] [Abstract][Full Text] [Related]
5. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.
Marín MQ; Pérez P; Gómez CE; Sorzano CÓS; Esteban M; García-Arriaza J
Viruses; 2018 Aug; 10(8):. PubMed ID: 30096846
[TBL] [Abstract][Full Text] [Related]
6. Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations.
Knudsen ML; Ljungberg K; Kakoulidou M; Kostic L; Hallengärd D; García-Arriaza J; Merits A; Esteban M; Liljeström P
J Virol; 2014 Nov; 88(21):12438-51. PubMed ID: 25122792
[TBL] [Abstract][Full Text] [Related]
7. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
[TBL] [Abstract][Full Text] [Related]
8. The combined vaccination protocol of DNA/MVA expressing Zika virus structural proteins as efficient inducer of T and B cell immune responses.
Pérez P; Martín-Acebes MA; Poderoso T; Lázaro-Frías A; Saiz JC; Sorzano CÓS; Esteban M; García-Arriaza J
Emerg Microbes Infect; 2021 Dec; 10(1):1441-1456. PubMed ID: 34213405
[TBL] [Abstract][Full Text] [Related]
9. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
10. Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
Tan WG; Zubkova I; Kachko A; Wells F; Adler H; Sutter G; Major ME
PLoS One; 2017; 12(7):e0181578. PubMed ID: 28732046
[TBL] [Abstract][Full Text] [Related]
11. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.
Swadling L; Capone S; Antrobus RD; Brown A; Richardson R; Newell EW; Halliday J; Kelly C; Bowen D; Fergusson J; Kurioka A; Ammendola V; Del Sorbo M; Grazioli F; Esposito ML; Siani L; Traboni C; Hill A; Colloca S; Davis M; Nicosia A; Cortese R; Folgori A; Klenerman P; Barnes E
Sci Transl Med; 2014 Nov; 6(261):261ra153. PubMed ID: 25378645
[TBL] [Abstract][Full Text] [Related]
12. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
[TBL] [Abstract][Full Text] [Related]
13. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
Zhao HP; Sun JF; Li N; Sun Y; Wang Y; Qiu HJ
Vet Immunol Immunopathol; 2009 Oct; 131(3-4):158-66. PubMed ID: 19411115
[TBL] [Abstract][Full Text] [Related]
14. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
15. A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.
Fournillier A; Frelin L; Jacquier E; Ahlén G; Brass A; Gerossier E; Holmström F; Broderick KE; Sardesai NY; Bonnefoy JY; Inchauspé G; Sällberg M
J Infect Dis; 2013 Sep; 208(6):1008-19. PubMed ID: 23776192
[TBL] [Abstract][Full Text] [Related]
16. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice.
Pancholi P; Perkus M; Tricoche N; Liu Q; Prince AM
J Virol; 2003 Jan; 77(1):382-90. PubMed ID: 12477843
[TBL] [Abstract][Full Text] [Related]
17. Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice.
Guan J; Deng Y; Chen H; Yin X; Yang Y; Tan W
Arch Virol; 2015 Oct; 160(10):2517-24. PubMed ID: 26215441
[TBL] [Abstract][Full Text] [Related]
18. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
[TBL] [Abstract][Full Text] [Related]
19. Broadening CD4
Filskov J; Mikkelsen M; Hansen PR; Christensen JP; Thomsen AR; Andersen P; Bukh J; Agger EM
J Virol; 2017 Jul; 91(14):. PubMed ID: 28446674
[TBL] [Abstract][Full Text] [Related]
20. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]